Delek Group is spinning the Leviathan royalty into a traded security, not direct reservoir ownership
The July 1 update sets up a 1:1 dividend in kind of Delek Development and Properties shares and expected trading on July 13. The move removes part of Delek Group's consolidated liabilities, but investors are getting a royalty cash-flow right derived from NewMed's Leviathan stake, not a working interest in the reservoir.
Delek Group has moved the Leviathan royalty separation from an idea into execution. The July 1 update lists a series of approvals already received: the Petroleum Commissioner's approval to transfer the royalty rights, court approval for a capital reduction of up to $175 million, a final tax ruling, and board approval to distribute Delek Development and Properties shares as a dividend in kind. The company also repaid about $28 million to the royalty company. The transaction creates a new traded security that will own the full super-royalty company and be listed separately. But that new security does not turn shareholders into direct Leviathan partners like NewMed Energy or Ratio Energies. Delek is extracting a cleaner royalty right from the holding-company layer, leaving investors with an asset that will be analyzed through royalty receipts, liquidity and the market's ability to distinguish a royalty from reservoir ownership. The restructuring is expected to remove about $220 million of net liabilities from Delek's consolidated balance sheet and increase Delek's equity by $200-220 million, but it does not change distributable surplus. The effect on Delek's holding-company discount now depends on whether Delek Development can create adequate liquidity and transparent disclosure, rather than just another listed line investors must analyze.
Delek Sets The Distribution Ratio And Timetable
The late-May filing laid out the transaction framework: Delek would list its holdings in Delek Leviathan Royalty by distributing Delek Development and Properties shares as a dividend in kind. Delek Development, an empty wholly owned subsidiary of Delek, is meant to become a sister company held by the same shareholders and in the same ownership ratios. The full holding in the royalty company will be transferred into it, so that Delek Development holds 100% of the super-royalty company and its shares are listed for trading.
The July 1 update turns that framework into a near-term sequence. The record date for receiving Delek Development shares is July 8, 2026. The distribution will be made at a ratio of one Delek Development ordinary share for each ordinary Delek share. By July 10, several additional steps are expected: Delek Energy will distribute its super-royalty holding as a dividend in kind to Delek, the royalty company will carry out a $170 million capital reduction by offsetting Delek loans to the royalty company, and Delek will approve the transfer of the royalty company to Delek Development.
Subject to completion of the technical steps with the Tel Aviv Stock Exchange and the registration company, trading in Delek Development shares is expected to begin on July 13, 2026. For the public-holdings test, Delek cites a price of about NIS 5.99 per Delek Development share, public holdings of about NIS 54 million and public holdings of 49.02%. Delek Development's equity after the capital reduction is expected to be about NIS 72 million. These are listing, distribution and maintenance-rule figures, not a full economic valuation of the royalty right over Leviathan's life.
A Royalty Is A Derived Cash-Flow Right
Pricing the new asset requires understanding the mechanism underneath it. The royalty company holds the right to receive royalties from oil, gas or other valuable substances produced and used from the Leviathan North and Leviathan South leases. The right is 1.5% before the investment payback date and 6.5% after that date, before wellhead adjustments, out of all of NewMed's rights in the reservoir, which stand at 45.34%.
That right is materially different from a direct working interest. Partnerships such as NewMed and Ratio own participation rights, bear their share of capex, debt, development decisions and production risk, and are exposed to the full reservoir economics of revenue, costs, taxes and distributions. Delek Development, by contrast, is expected to receive a right to a payment derived from Leviathan production and use out of NewMed's share. The royalty can benefit from volume growth, gas and condensate prices, and the higher royalty rate after payback. Still, it does not provide operator control or a seat in investment decisions, and its cash flow is derived from the contractual royalty mechanism rather than from the reservoir's full net income line.
| Economic Question | Leviathan Royalty Through Delek Development | Direct Reservoir Holding |
|---|---|---|
| Where Cash Comes From | Payment derived from production and use out of NewMed's share | Reservoir revenue after costs, taxes, royalties and investment |
| Operating control | None | Limited to the reservoir partners and operator under the partnership agreements |
| Exposure to development capex | Indirect, through the effect of expansion on royalty cash flow | Direct, according to the ownership share |
| What the market must price | Royalty rate, payback date, cash flow, liquidity and disclosure | Reserves, sales, costs, financing, distributions and development decisions |
The transaction isolates a specific economic component, the super-royalty, and places it in a separate security. Accurate pricing of that component could improve transparency for an asset that was previously embedded inside the holding company. The risk is that investors fail to distinguish between a royalty and a working interest. That confusion can lead to poor pricing and may deepen the holding-company discount rather than reduce it.
Balance Sheet Cleanup Is Not New Parent Cash Flow
The update presents a meaningful balance-sheet effect: removal of about $220 million of net liabilities from Delek's consolidated balance sheet, alongside an expected $200-220 million increase in equity. For a holding company, lower consolidated leverage can improve financial flexibility and the ability to service debt or invest.
However, Delek also states that the restructuring does not affect distributable surplus. The transaction changes how the asset is held, but it does not create a new cash source at the parent company. Shareholders will receive separately traded Delek Development shares, but Delek Group's cash balance does not increase because of that distribution. Parent-level debt service and dividends will continue to depend on cash that actually moves up from NewMed, Ithaca and other holdings, after financing costs and investments.
The royalty separation gives an asset with distinct economics its own price, liquidity and disclosure. Its success will depend on the quality of future disclosure. Without a clear cash-flow model, sensitivity to volumes and prices, and a transparent follow-up on the payback date, investors will struggle to price the new security. In that case, complexity simply moves from Delek Group's balance sheet to another listed line on the exchange.
The Next Steps Before Independent Trading
In the immediate term, the market will watch the completion of the capital split, listing of Delek Development shares, and transfers among Delek Energy, Delek Group and Delek Development. Delek's ex price will also need to reflect the distribution without unusual trading distortion. Delek states that the ex price will be calculated based on Delek's July 7 share price and the equity ratio between Delek and Delek Development, about 0.8%. In the company's example based on the June 29 share price, Delek's share price would be reduced by about NIS 5.99 to about NIS 751.
After trading begins, the focus shifts to Delek Development's disclosure quality. Investors will examine how it presents royalty cash flow, separates the pre-payback and post-payback periods, explains wellhead adjustments, and what level of liquidity develops in the share. Those data points are necessary for pricing the royalty right economically, beyond the legal wrapper.
This is a capital-structure event rather than a routine update on gas demand or production expansion. Delek is extracting the Leviathan royalty right from the holding company and handing the market a chance to price it directly. Smooth trading and detailed disclosure would give investors a cleaner way to read the Leviathan royalty. Thin liquidity or confusion between a royalty and direct reservoir ownership would leave Delek's holding-company discount intact and add one more analytical layer for Delek investors.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.